Skip to main content
OpenTrials
Completed

NCT Number: NCT05084729

CONFIDENCE Registry

This registry has been designed to obtain real-life, post-market data on the use of the Imagio breast imaging system. This registry is sponsored by Seno Medical Instruments, Inc., the manufacturer of the device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Rijnstate Hospital, Arnhem, Netherlands

Loading trial locations.

About this study

This is a prospective, controlled, multi-center, observational international registry designed to evaluate the Imagio breast imaging system. The registry will be conducted at up to 12 international centers. Investigators will use Imagio US (IUS) and/or Imagio OA/US imaging per standard of care, anddata will be collected accordingly. Additional imaging and biopsy/surgery will be conducted per standard of care to reach a final diagnosis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Subjects must meet all the following criteria to be included in the registry:

  • Have been informed of the nature of the registry and provided written informed consent, prior to initiation of any registry activities,
  • Are females 18 years of age or older at the time of consent,
  • Have been referred for a breast US and are subject to treatment with the Imagio breast imaging system.

Exclusion criteria

- Aligned with the contraindications on the use of the device, subjects who meet any of the following criteria will be excluded from the registry:

  • Are pregnant.
  • Have open sores including insect bites, rash, poison ivy, and chafing on the skin of the ipsilateral breast.
  • Are experiencing photo-toxicity associated with currently taking, or having taken, photosensitizing agents within the previous 72 hours such as sulfa, ampicillin, tetracycline.
  • Are currently undergoing phototherapy.
  • Have a history of any photosensitive disease (e.g., porphyria, lupus erythematosus).
  • Are undergoing treatment for a photosensitive disease and is experiencing photosensitivity.
  • Have previously participated in this registry,
  • Are currently enrolled in another investigational study or registry that would directly interfere with the current registry.

Treatment and study plan

Imagio OA/US

Device

Imagio optoacoustic

Primary outcomes

  1. Specificity, negative likelihood ratio, sensitivity and positive likelihood

    Time frame: September 2024

    This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations

  2. Assessment of the percentage of masses that the Imagio system alone or in combination with other imaging modalities is indicated as impacting the decision to biopsy

    Time frame: September 2024

    This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations

  3. Quality of Life Assessment - Testing Morbidity Index

    Time frame: September 2024

    This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations

  4. In malignant breast masses, to assess the roles of the Imagio OA/US as a prognostic biomarker

    Time frame: September 2024

    i.e., the correlation of Imagio OA/US feature scoring with histologic grade, ER and PR hormone receptors, HER2 receptor (IHC and/or HER2 FISH), Ki-67 proliferative index, as well as with molecular subtypes of breast cancer.

    This parameter will be reviewed for the Intention-to-Diagnose (ITD) and Per-Protocol (PP) populations

Secondary outcomes

  1. Characteristics of lymph node lesions/masses the device is used for

    Time frame: September 2024

    This parameter will be reviewed for the Safety population

  2. Incidence and nature of device deficiencies (i.e. device complaints, device malfunctions)

    Time frame: September 2024

    This parameter will be reviewed for the Safety population

  3. Incidence and nature of device and procedure related adverse events

    Time frame: September 2024

    This parameter will be reviewed for the Safety population

Sponsors and collaborators

Lead sponsor

Seno Medical Instruments Inc.

Industry

Collaborators

  • American College of Radiology

Registry information

Official study title

A Multi-Center InternatiONal Registry to Evaluate the Efficacy oF Imaging With Opto-acoustics to Diagnose BrEast CaNCEr

Acronym: CONFIDENCE

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Oct 20, 2021
Registry last updated
Oct 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.